Giovanni Ponti1, Marco Manfredini2, Stefano Greco3, Giovanni Pellacani2, Roberta Depenni3, Aldo Tomasi4, Monia Maccaferri2, Stefano Cascinu3. 1. Department of Surgical, Medical, Dental and Morphological Sciences with Interest Transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy giovanni.ponti@unimore.it. 2. Department of Surgical, Medical, Dental and Morphological Sciences with Interest Transplant, Oncological and Regenerative Medicine, University of Modena and Reggio Emilia, Modena, Italy. 3. Department of Oncology, University of Modena and Reggio Emilia, Modena, Italy. 4. Department of Diagnostic and Clinical Medicine and Public Health, University of Modena and Reggio Emilia, Modena, Italy.
Abstract
BACKGROUND/AIM: The mutational status of stage III and IV melanomas should be recognized in order to allow for targeted therapies. The aim of our study was the characterization of BRAF, NRAS and C-KIT melanoma patients, in order to define their optimal management. PATIENTS AND METHODS: Between 1991 and 2015, 63 mutated melanoma patients were treated and monitored during their diagnostic and therapeutic management at a single institution. RESULTS: BRAF-mutated melanoma patients were the most common, representing 70% of the study population, while NRAS- and C-KIT-mutated melanoma represented 19% and 11% respectively. BRAF-mutated melanomas were mostly located at sites of intermittent sun exposure, and were associated with higher Breslow thickness and an increased number of mitosis. NRAS mutated melanoma were mainly observed in chronic sun-damaged areas and had a negative prognostic value, with shorter time to progression and a high incidence of central nervous system involvement. C-KIT mutated melanoma were located at acral and mucosal sites. Overall survival observed in the three groups of patients revealed wide differences. CONCLUSION: BRAF, NRAS and C-KIT melanomas constitute distinct clinico-pathological entities. BRAF-mutated melanoma benefit from both anti-BRAF and anti-MEK targeted therapies while triple-negative melanomas could benefit from novel anti-CTLA-4 and anti-PD-L1 immunotherapeutic approaches. Copyright
BACKGROUND/AIM: The mutational status of stage III and IV melanomas should be recognized in order to allow for targeted therapies. The aim of our study was the characterization of BRAF, NRAS and C-KITmelanomapatients, in order to define their optimal management. PATIENTS AND METHODS: Between 1991 and 2015, 63 mutated melanomapatients were treated and monitored during their diagnostic and therapeutic management at a single institution. RESULTS:BRAF-mutated melanomapatients were the most common, representing 70% of the study population, while NRAS- and C-KIT-mutated melanoma represented 19% and 11% respectively. BRAF-mutated melanomas were mostly located at sites of intermittent sun exposure, and were associated with higher Breslow thickness and an increased number of mitosis. NRAS mutated melanoma were mainly observed in chronic sun-damaged areas and had a negative prognostic value, with shorter time to progression and a high incidence of central nervous system involvement. C-KIT mutated melanoma were located at acral and mucosal sites. Overall survival observed in the three groups of patients revealed wide differences. CONCLUSION:BRAF, NRAS and C-KITmelanomas constitute distinct clinico-pathological entities. BRAF-mutated melanoma benefit from both anti-BRAF and anti-MEK targeted therapies while triple-negative melanomas could benefit from novel anti-CTLA-4 and anti-PD-L1 immunotherapeutic approaches. Copyright
Authors: Tithi Roy; Samuel T Boateng; Sergette Banang-Mbeumi; Pankaj K Singh; Pratik Basnet; Roxane-Cherille N Chamcheu; Federico Ladu; Isabel Chauvin; Vladimir S Spiegelman; Ronald A Hill; Konstantin G Kousoulas; Bolni Marius Nagalo; Anthony L Walker; Jean Fotie; Siva Murru; Mario Sechi; Jean Christopher Chamcheu Journal: Bioorg Chem Date: 2020-12-30 Impact factor: 5.275
Authors: Giovanni Ponti; Giovanni Pellacani; Aldo Tomasi; Roberta Depenni; Monia Maccaferri; Antonio Maiorana; Giulia Orsi; Francesca Giusti; Stefano Cascinu; Marco Manfredini Journal: Mol Clin Oncol Date: 2019-11-07
Authors: Raluca Cristina Apostu; Elena Stefanescu; Radu Razvan Scurtu; Gabriel Kacso; Radu Drasovean Journal: World J Clin Cases Date: 2021-12-26 Impact factor: 1.337